Velocity’s Valparaiso research site was founded in 2004 by Dr. Robert Buynak as Buynak Clinical Research, an independent dedicated research center, and acquired by Velocity in 2020. Our Valparaiso site conducts studies in a number of internal medicine indications, with particular expertise in diabetes and other metabolic disorders, such as obesity, COPD and emphysema trials. More recently, this site has expanded into arthritis, pain indications, and vaccine trials. With more than 5,000 square-feet of dedicated research space, our staff can efficiently and effectively conduct multiple concurrent studies.
Located adjacent to Valparaiso University and close to a regional hospital, this site offers easy access from a major highway and free parking. Valparaiso is situated half-way between Southside Chicago and South Bend, IN with access to a diverse population of potential study participants from this area.
All trials conducted at the site are performed in accordance with ICH and FDA guidelines, and in compliance with GCP. The Valparaiso team is committed to being a resource for study participants, to providing the highest quality of patient care with compassion and kindness, and to advancing medicine through research.